Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 6/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.53 |
| ▸ | SIRT2 | Q8IXJ6 | 11/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 10/20 | 0.53 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8495706 | 0.97 | CTSL (0.54) | SIRT5HDAC1SIRT2SIRT1 | |
| SCHEMBL8495526 | 0.97 | CTSL (0.54) | SIRT5HDAC1SIRT2SIRT1 | |
| SCHEMBL9490221 | 0.96 | SIRT5 (0.53) | SIRT5HDAC1SIRT2SIRT1SIRT3 | |
| SCHEMBL8342384 | 0.90 | HDAC1 (0.49) | SIRT5HDAC1SIRT2SIRT1SIRT3 | |
| Hydrochloric Acid SCHEMBL9814916 | 0.89 | HDAC1 (0.48) | SIRT5HDAC1SIRT2SIRT1SIRT3 | |
| SCHEMBL3868955 | 0.88 | SIRT5 (0.52) | SIRT5 | |
| SCHEMBL3868962 | 0.88 | SIRT5 (0.52) | SIRT5 | |
| SCHEMBL9490193 | 0.87 | SIRT2 (0.48) | SIRT5HDAC1SIRT2SIRT1SIRT3 | |
| SCHEMBL9488093 | 0.86 | SIRT1 (0.51) | SIRT5SIRT2SIRT1SIRT3 | |
| SCHEMBL1587596 | 0.86 | SIRT1 (0.51) | SIRT5SIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130273035-A1 | Methods and Compositions for Reducing Amyloid Beta Levels | THE J. DAVID GLADSTONE INSTITUTES | 2013-10-17 | — | — | US | claimed |
| US-9347085-B2 | Methods and compositions for reducing amyloid beta levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2016-05-24 | — | — | US | disclosed |
| EP-2094832-B1 | METHODS AND COMPOSITIONS FOR REDUCING AMYLOID BETA LEVELS | DAVID GLADSTONE INST (US) | 2015-04-22 | — | — | EP | disclosed |
| US-20140234302-A1 | Methods and Compositions for Reducing Amyloid Beta Levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130273035-A1 | Methods and Compositions for Reducing Amyloid Beta Levels | THE J. DAVID GLADSTONE INSTITUTES | 2013-10-17 | — | — | US | disclosed |
| US-8420613-B2 | Methods and compositions for reducing amyloid beta levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-04-16 | — | — | US | disclosed |
| US-8388953-B2 | Method of increasing cathepsin B-induced cleavage of amyloid-β peptides | THE J. DAVID GLADSTONE INSTITUTES (US) | 2013-03-05 | — | — | US | disclosed |
| US-20110256120-A1 | Methods and Compositions for Reducing Amyloid Beta Levels | THE J. DAVID GLADSTONE INSTITUTES | 2011-10-20 | — | — | US | disclosed |
| US-7951367-B2 | Using cathepsin variant as therapeutic tool in treatment and prevention of nervous system disorders | THE J. DAVID GLADSTONE INSTITUTES (US) | 2011-05-31 | — | — | US | disclosed |
| US-20100040612-A1 | METHODS AND COMPOSITIONS FOR REDUCING AMYLOID BETA LEVELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-02-18 | — | — | US | disclosed |
| US-20040247527-A1 | Multifunctional photodynamic agents for treating of disease | MPA TECHNOLOGIES, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040146463-A1 | Functional MRI agents for cancer imaging | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-07-29 | — | — | US | disclosed |
| US-6673333-B1 | COMPRISING A FIRST GD(III) ION BOUND TO A FIRST CHELATOR; GD(III) ION HAS COORDINATION ATOMS IN AT LEAST 7 COORDINATION SITES; BOUND TO TUMOR ASSOCIATED ACTIVATIVLE GUARDING MOIETY | RESEARCH CORPORATION TECHNOLOGIES, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | METAPROBE, INC. | 2003-01-30 | — | — | US | disclosed |
| EP-1278552-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2002080757-A2 | NOVEL FUNCTIONAL AGENTS FOR MAGNETIC RESONANCE IMAGING | METAPROBE, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| WO-2001082976-A2 | FUNCTIONAL MRI AGENTS FOR CANCER IMAGING | RESEARCH CORPORATION TECHNOLOGIES (US) | 2001-11-08 | — | — | WO | disclosed |
| EP-0255341-B1 | REAGENT FOR TESTING PERIODONTAL DISEASES | SUNSTAR KABUSHIKI KAISHA (JP) | 1993-02-03 | — | — | EP | disclosed |
| US-5137811-A | Method for diagnosing periodontal diseases with a substrate specific for aminopeptidase activity of periodontopathic bacteria | SUNSTAR KABUSHIKI KAISHA (JP) | 1992-08-11 | — | — | US | disclosed |
| EP-0255341-A2 | Reagent for testing periodontal diseases | SUNSTAR KABUSHIKI KAISHA (JP) | 1988-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030021750-A1 | Novel functional agents for magnetic resonance imaging | FABP7, RXFP1, MRGPRX2 | SIRT5 2598/4885HDAC1 4418/4885SIRT2 2784/4885 |
| US-20040146463-A1 | Functional MRI agents for cancer imaging | TSG101, SMARCE1, SMARCA1 | SIRT5 465/4885HDAC1 2568/4885SIRT2 1517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.